Anti-Human Phosphorylcholine Recombinant Antibody (M99-B05) (CAT#: TAB-0941CL)
This antibody is capable of binding to phosphorylcholine or a phosphorylcholine conjugate, having surprisingly effective in vivo properties, such as inhibiting vessel wall thickening after cuff-induced vascular injury.
Specific Inquiry
ELISA
Figure 1 Antibody binding efficacy by 27 clones to BSA-PC, measured through ELISA (expressed as OD).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
ELISA
Figure 2 Nine selected antibody clones, their affinity to PC, measured through ELISA (expressed as OD).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
ELISA
Figure 3 Nine selected antibody clones, their affinity to oxLDL, measured through ELISA (expressed as OD).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
FuncS
Figure 4 Cuff arteries of ApoE3 * Leiden mice receiving human anti-streptavidin, anti-PC T15, M99-B05 or X9-C01, white blood cells and macrophages as a percentage of total cells after 3 days.
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
FuncS
Figure 5 The cuff arteries of ApoE3 * Leiden mice receiving human anti-streptavidin, anti-PC T15, M99-B05 or X9-C01, and the percentage of cells expressing MCP-1 after 14 days.
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
IF
Figure 6 Representative cross-section MCP-1 staining of the cuff arteries of ApoE3 * Leiden mice after 3 days of treatment with human anti-streptavidin, anti-PC T15, M99-B05 or X9-C01.
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
IF
Figure 7 Representative cross-section Weigert elastin staining of the cuff arteries of ApoE3 * Leiden mice receiving human anti-streptavidin, M99-B05 14 days.
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
FuncS
Figure 8 After treatment with human anti-streptavidin, anti-PC T15, M99-B05 or X9-C01, the cuff artery intima of ApoE3 * Leiden mice thickened.
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
FuncS
Figure 9 Quantitative ratio of cuff arterial intima / medium of ApoE3 * Leiden mice after treatment with human anti-streptavidin, anti-PC T15, M99-B05 or X9-C01.
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
IF
Figure 10 Atherosclerotic coronary arterial sections (anti-PC M99-B05 staining, 10-80x magnification).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
ELISA
Figure 11 PC-affinity by seven M99-B05 clones, measured by ELISA (expressed as OD).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
IF
Figure 12 Representative cross-sections of cuffed arteries of ApoE3*Leiden mice receiving human anti-streptavidin, M99- B05 or X19-A05 (0.5, 2, 10mg/kg) after 14d (Weigert’s elastin staining, magnification 40x).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
IHC
Figure 13 Representative sections of IHC studies of human disease-free and atherosclerotic aortic tissue (anti-PC M99B05 and HRP streptavidin staining, 20x magnification).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
WB
Figure 14 Western blot analysis with HRPconjugated goat anti-human IgG.
Both antibodies are stable in serum under the tested conditions, as evidenced by the lack of degradation in the band intensity of the heavy chain (band above the 49kDa marker) and the light chain (band near the 28 kDa marker).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
WB
Figure 15 Western blot analysis with HRPconjugated streptavidin.
Both antibodies are stable in serum under the tested conditions, as evidenced by the lack of degradation in the band intensity of the heavy chain (band above the 49kDa marker) and the light chain (band near the 28 kDa marker).
Ewing, M. M., Karper, J. C., Nordzell, M., Karabina, S. A. P., Atout, R., Sexton, D., ... & Frostegård, J. Optimizing natural occurring IgM antibodies for therapeutic use: inflammatory vascular disease treatment with anti-phosphorylcholine IgG.
Specifications
- Host Species
- Human
- Derivation
- Phage display library
- Type
- Human antibody
- Specificity
- Human
- Clone
- M99-B05
- Applications
- ELISA, FuncS, IHC, WB, IF
- Related Disease
- Cuff-induced vascular injury
Applications
- Application Notes
- The antibody was validated for ELISA, Functional Assay, Immunohistochemistry, Western Blot, Immunofluorescence. For details, refer to Published Data.
Target
- Alternative Names
- Phosphorylcholine
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone M99-B05"
See other products for "Phosphorylcholine"
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-773 | Recombinant Anti-Phosphorylcholine Antibody | WB, Neut, FuncS | IgG |
| MHH-773 | Recombinant Human Anti-Phosphorylcholine Antibody | IF, Neut, FuncS | IgG |
| FAMAB-0263CQ | Mouse Anti-Phosphorylcholine Recombinant Antibody (clone 511) | ELISA | Mouse IgG |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-773-F(E) | Recombinant Anti-Phosphorylcholine Antibody Fab Fragment | RIA, ELISA, FuncS | Fab |
| MHH-773-F(E) | Recombinant Human Anti-Phosphorylcholine Antibody Fab Fragment | WB, Dot, FuncS | Fab |
| FAMAB-0263CQ-F(E) | Mouse Anti-Phosphorylcholine Recombinant Antibody (clone 511); Fab Fragment | ELISA | Mouse Fab |
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-773-S(P) | Recombinant Anti-Phosphorylcholine Antibody scFv Fragment | FC, WB, FuncS | scFv |
| MHH-773-S(P) | Recombinant Human Anti-Phosphorylcholine Antibody scFv Fragment | IF, Neut, FuncS | scFv |
| FAMAB-0263CQ-S(P) | Mouse Anti-Phosphorylcholine Recombinant Antibody (clone 511); scFv Fragment | ELISA | Mouse scFv |
Human Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-0389CL | Human Anti-Phosphorylcholine Recombinant Antibody (TAB-0389CL) | ELISA, FACS, Inhib, IHC | Human IgG |
| TAB-0390CL | Human Anti-Phosphorylcholine Recombinant Antibody (TAB-0390CL) | ELISA, In vivo | Human IgG |
| TAB-0391CL | Human Anti-Phosphorylcholine Recombinant Antibody (TAB-0391CL) | ELISA, In vivo | Human IgG |
| TAB-0941CL-F(E) | Anti-Human Phosphorylcholine Recombinant Antibody Fab Fragment (M99-B05) | ELISA | Human antibody |
| TAB-0942CL-F(E) | Anti-Human Phosphorylcholine Recombinant Antibody Fab Fragment (X19-A01) | ELISA | Human antibody |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for TAB-0941CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.